Puma Biotechnology, Inc.

NasdaqGS:PBYI Stock Report

Market Cap: US$256.9m

Puma Biotechnology Past Earnings Performance

Past criteria checks 5/6

Puma Biotechnology has been growing earnings at an average annual rate of 52.3%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been declining at an average rate of 4.1% per year. Puma Biotechnology's return on equity is 40.4%, and it has net margins of 9.2%.

Key information

52.3%

Earnings growth rate

53.2%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-4.1%
Return on equity40.4%
Net Margin9.2%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Mar 01
There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Dec 27
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Sep 08
Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Apr 17
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Dec 14
We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Sep 20

Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Sep 05
Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M

Aug 04

Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?

Jun 04
Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?

Puma Bio: Still Worthy Of Consideration After Earnings Surprise

Mar 08

Puma Bio: Recent Sell-Off Brings My Position Out Of Mothball

Aug 13

Revenue & Expenses Breakdown
Beta

How Puma Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:PBYI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23236228950
30 Sep 2322949551
30 Jun 23230-29651
31 Mar 2323559250
31 Dec 2222809252
30 Sep 22218108753
30 Jun 22207-349060
31 Mar 22201-4910867
31 Dec 21253-2911672
30 Sep 21250-4812282
30 Jun 21255-3512686
31 Mar 21272-2711692
31 Dec 20225-6011898
30 Sep 20235-56120104
30 Jun 20241-42122110
31 Mar 20224-82126123
31 Dec 19272-76140133
30 Sep 19280-95151141
30 Jun 19287-92148147
31 Mar 19284-99155154
31 Dec 18251-114146165
30 Sep 18202-147136177
30 Jun 18145-210140190
31 Mar 1894-243125200
31 Dec 1728-292107208
30 Sep 176-30192214
30 Jun 170-28974216
31 Mar 170-27861217
31 Dec 160-27654223
30 Sep 160-26547219
30 Jun 160-26042219
31 Mar 160-25835224
31 Dec 150-23932208
30 Sep 150-22530196
30 Jun 150-20025176
31 Mar 150-17524151
31 Dec 140-14219123
30 Sep 140-1101496
30 Jun 140-891376
31 Mar 140-631152
31 Dec 130-551045
30 Sep 130-612040
30 Jun 130-722646

Quality Earnings: PBYI has high quality earnings.

Growing Profit Margin: PBYI's current net profit margins (9.2%) are higher than last year (0%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PBYI has become profitable over the past 5 years, growing earnings by 52.3% per year.

Accelerating Growth: PBYI's earnings growth over the past year (1079450%) exceeds its 5-year average (52.3% per year).

Earnings vs Industry: PBYI earnings growth over the past year (1079450%) exceeded the Biotechs industry -8.9%.


Return on Equity

High ROE: Whilst PBYI's Return on Equity (40.4%) is outstanding, this metric is skewed due to their high level of debt.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.